Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 95
Selected: 0
NCT IDTitle
NCT04414475A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
NCT05980806A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT01607892Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
NCT02146833SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
NCT02389543Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
NCT02831686A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
NCT03071276Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT04421378A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT02228525Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
NCT04984330Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
NCT07479979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT05597345Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
NCT02416908Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
NCT05983276Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
NCT03955783Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
NCT03110562Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT05177276Selinexor Combination Ph 1 Study
NCT03880123Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
NCT02137356Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
NCT05093608SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
NCT05530421Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT02649790Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
NCT03095612Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
NCT07200102Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT04607772Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02431351Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
NCT04562870A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04782687Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04856189Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
NCT02431364Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
NCT04256707Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
NCT01607905Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
NCT02343042Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02299518Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01896505A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
NCT04925193Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02702492PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
NCT02025985Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
NCT02741388A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
NCT05028348A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT03466827Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
NCT07447817Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
NCT02536495Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
NCT05820763Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
NCT02628704Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
NCT02351505Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
NCT02606461Selinexor in Advanced Liposarcoma
NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma